Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
2.190
-0.100 (-4.37%)
At close: Jul 25, 2025, 4:00 PM
2.190
0.00 (0.00%)
After-hours: Jul 25, 2025, 7:57 PM EDT
Telomir Pharmaceuticals Employees
As of December 31, 2023, Telomir Pharmaceuticals had 9 total employees, including 1 full-time and 8 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,384,215
Market Cap
65.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TELO News
- 1 day ago - Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's - Accesswire
- 7 days ago - Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin - Accesswire
- 5 weeks ago - Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - Accesswire
- 6 weeks ago - Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - Accesswire
- 7 weeks ago - Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Accesswire
- 7 weeks ago - Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Accesswire
- 2 months ago - Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Accesswire
- 2 months ago - Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - Accesswire